Fatal Anaphylaxis After Intravenous Iron Dextran

    Volume 20, Issue 2 (April 1975)

    ISSN: 0022-1198


    Published Online: 1 April 1975

    Page Count: 8

    Zipf, RE
    Pathologist, Riverside Hospital Laboratories, Columbus, Ohio

    (Received 10 June 1974; accepted 6 August 1974)


    Iron dextran (Imferon®) is a complex of ferric iron and dextran widely used for the treatment of iron deficiency anemia. It became commercially available in the United States in 1957. Since that time the intramuscular administration of iron dextran has been considered a relatively safe manner of administering iron to patients unable to tolerate oral iron therapy. However, untoward side effects have been reported. The most common of these are discomfort or staining of the skin at the injection site. The more disturbing reactions, however, appear to be allergic in nature and include lymphadenopathy, fever, urticaria, angioneurotic edema, arthralgias, and transient shocklike conditions [1–5]. Recently four cases of fatal anaphylaxis following intramuscular injection of iron dextran have been reported [6,7].

    Paper ID: JFS10279J

    DOI: 10.1520/JFS10279J

    ASTM International
    is a member of CrossRef.

    Title Fatal Anaphylaxis After Intravenous Iron Dextran
    Symposium , 0000-00-00
    Committee E30